Penetration of telithromycin (HMR 3647), a new ketolide antimicrobial, into inflammatory blister fluid following oral administration.
The penetration of telithromycin (HMR 3647), a novel ketolide antimicrobial, has been assessed in an open, single-dose study in eight healthy male subjects. Following a single, oral, 600 mg dose the mean ratio of the concentration of telithromycin in blister fluid over plasma was 1.38. Significant blister fluid concentrations were maintained up to 24 h post-dose. These results indicate that telithromycin penetrates well into inflammatory extracellular fluid, achieving high and sustained concentrations in this medium.
Namour
F
F
Aventis Pharma, Hoechst Marion Roussel/Romainville, 102 Route de Noisy, 93235 Romainville, France. florence.namour@aventis.com
Sultan
E
E
Pascual
M H
MH
Lenfant
B
B
D000284:Administration, Oral; D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D019540:Area Under Curve; D001768:Blister / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology*; D005110:Extracellular Space / Q000378:metabolism*; D006801:Humans; D007249:Inflammation / Q000188:drug therapy; D048628:Ketolides; D018942:Macrolides; D008297:Male; D008875:Middle Aged
D000900:Anti-Bacterial Agents; D048628:Ketolides; D018942:Macrolides; C106791:telithromycin